AI Article Synopsis
- * CHF is a worsening condition with a high chance of death and hospital readmissions, so consistent monitoring and timely therapy adjustments are crucial for improving patient outcomes.
- * The outpatient unit aims to increase the follow-up care for CHF patients through preventive counseling and telemedicine, targeting early detection of those at high risk for disease progression, ultimately enhancing their quality and length of life.
Article Abstract
These guidelines combine the key provisions for the management of patients with chronic heart failure (CHF) at the outpatient stage based on current data from clinical studies, new 2024 clinical guidelines of the Russian Society of Cardiology for the management of CHF patients, and the provisions of the current order of the Ministry of Health of the Russian Federation on the procedure for conducting dispensary observation. CHF is a progressive disease characterized by a high risk of death, rehospitalizations, and disability. Reducing the risk of CHF decompensation and improving the prognosis is possible only with regular monitoring of the patient's condition and timely correction of therapy. The priority task of the outpatient unit is to expand the coverage of dispensary follow-up of CHF patients, preventive counseling, and telemedicine monitoring for timely identification of the patients at a high risk of CHF progression, improving their quality of life, and prolonging their life duration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18087/cardio.2024.11.n2797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redo Surgical Aortic Valve Replacement versus Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprosthetic Valves.
Ann Thorac Surg
January 2025
Division of Cardiothoracic Surgery, University of Virginia Health University Hospital, Charlottesville, VA.
Background: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with improved perioperative safety compared to redo surgical aortic valve replacement (redo-SAVR), but long-term outcomes remain uncertain. We therefore compare long-term outcomes of ViV-TAVR and redo-SAVR.
Methods: The study included 1:1 propensity-matched Medicare beneficiaries with degenerated bioprosthetic valves admitted between 09/29/2011 and 12/30/2020 undergoing either redo-SAVR or ViV-TAVR.
Circulating neuropeptide Y dynamics and performance during exercise in heart failure patients with contemporary medical and device therapy.
Exp Physiol
January 2025
Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
High cardiac sympathetic drive and release of the sympathetic cotransmitter neuropeptide Y (NPY) are significant features of congestive heart failure (CHF), in which resting venous NPY levels are known to be associated with mortality. However, whether circulating NPY levels increase during exercise in CHF when they are already elevated is controversial. We sought to establish the dynamics of circulating NPY levels in CHF patients treated with contemporary medical therapy and devices in relationship to indices of performance linked to long-term prognosis.
View Article and Find Full Text PDFIncidence and Impact of Myocarditis in Genetic Cardiomyopathies: Inflammation as a Potential Therapeutic Target.
Genes (Basel)
January 2025
Institute of Clinical Medicine, V.N. Vinogradov Faculty Therapeutic Clinic, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
Background: Myocardial disease is an important component of the wide field of cardiovascular disease. However, the phenomenon of multiple myocardial diseases in a single patient remains understudied.
Aim: To investigate the prevalence and impact of myocarditis in patients with genetic cardiomyopathies and to evaluate the outcomes of myocarditis treatment in the context of cardiomyopathies.
Heterogeneity across outcomes in clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic heart failure: cross-sectional study.
J Clin Epidemiol
January 2025
Center for Evidence-Based Medicine and Healthcare, Catholic University of Croatia, Zagreb, Croatia. Electronic address:
Objectives: This study aimed to analyze the outcomes, outcome domains, and prevalence of the use of clinical outcome endpoints (COE) in clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors for chronic heart failure (CHF) registered on ClinicalTrials.gov and compare them to COE for cardiovascular trials.
Study Design And Setting: We conducted a cross-sectional methodological study.
Introduction: Heart failure (HF) poses a substantial burden on healthcare systems and society, necessitating effective diagnostic tools for enhanced patient management. The soluble suppression of tumorigenesis 2 protein (Soluble Suppression of Tumorigenesis 2 (sST2)) has emerged as a promising biomarker linked to cardiac remodeling and fibrosis. This study investigates Soluble Suppression of Tumorigenesis 2 (sST2)'s potential as a diagnostic and prognostic marker for chronic heart failure (CHF) and explores its clinical utility in predicting outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!